ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced today that it has received notice from The NASDAQ Stock Market ("NASDAQ") stating that for 30 consecutive business days the bid price for the Company's common stock has closed below the minimum $1.00 per share as required by Marketplace Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market. This notification has no effect on the listing of the Company's common stock at this time.
